更新于：2024-12-09
Bumetanide
布美他尼
更新于：2024-12-09
概要
基本信息
药物类型 小分子化药 |
别名 3-(aminosulfonyl)-5-(butylamino)-4-phenoxybenzoic acid、3-butylamino-4-(phenoxy)-5-sulfamoylbenzoic acid、3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid + [19] |
作用机制 NKCC1抑制剂(溶质载体家族12成员2抑制剂)、NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂)、SLC12A4抑制剂(solute carrier family 12 member 4 inhibitors) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 日本 (1976-04-08), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C17H20N2O5S |
InChIKeyMAEIEVLCKWDQJH-UHFFFAOYSA-N |
CAS号28395-03-1 |
关联
49
项与 布美他尼 相关的临床试验中国健康受试者单次口服布美他尼片（1mg）的开放、随机、单剂量、两制剂、单次给药、交叉设计的生物等效性试验
Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial
Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Bumetanide in Patients With Alzheimer's Disease.
100 项与 布美他尼 相关的临床结果
登录后查看更多信息
100 项与 布美他尼 相关的转化医学
登录后查看更多信息
100 项与 布美他尼 相关的专利（医药）
登录后查看更多信息
2,699
项与 布美他尼 相关的文献（医药）2025-01-01PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part II: The future
Review
作者: Arango, Celso ; Asta, Lisa ; Cortese, Samuele ; Persico, Antonio M. ; Persico, Antonio M ; Vitiello, Benedetto ; Chehbani, Fethia ; Parlatini, Valeria ; Mirabelli, Silvestro
Part I of this systematic review summarized the state-of-the-art of pediatric psychopharmacology for Autism Spectrum Disorder (ASD), a severe and lifelong neurodevelopmental disorder. The purpose of this Part II follow-up article is to provide a systematic overview of the experimental psychopharmacology of ASD. To this aim, we have first identified in the Clinicaltrials.gov website all the 157 pharmacological and nutraceutical compounds which have been experimentally tested in children and adolescents with ASD using the randomized placebo-controlled trial (RCT) design. After excluding 24 drugs already presented in Part I, a systematic review spanning each of the remaining 133 compounds was registered on Prospero (ID: CRD42023476555), performed on PubMed (August 8, 2024), and completed with EBSCO, PsycINFO (psychology and psychiatry literature) and the Cochrane Database of Systematic reviews, yielding a total of 115 published RCTs, including 57 trials for 23 pharmacological compounds and 48 trials for 17 nutraceuticals/supplements. Melatonin and oxytocin were not included, because recent systematic reviews have been already published for both these compounds. RCTs of drugs with the strongest foundation in preclinical research, namely arbaclofen, balovaptan and bumetanide have all failed to reach their primary end-points, although efforts to target specific patient subgroups do warrant further investigation. For the vast majority of compounds, including cannabidiol, vasopressin, and probiotics, insufficient evidence of efficacy and safety is available. However, a small subset of compounds, including N-acetylcysteine, folinic acid, l-carnitine, coenzyme Q10, sulforaphane, and metformin may already be considered, with due caution, for clinical use, because there is promising evidence of efficacy and a high safety profile. For several other compounds, such as secretin, efficacy can be confidently excluded, and/or the data discourage undertaking new RCTs. Part I and Part II summarize "drug-based" information, which will be ultimately merged to provide clinicians with a "symptom-based" consensus statement in a conclusive Part III, with the overarching aim to foster evidence-based clinical practices and to organize new strategies for future clinical trials.
2024-12-02American Journal of Audiology
Ototoxic Drug Exposure and Hearing Loss in Neonates: A Scoping Review
Review
作者: Rameshsankar, Subaasri ; Seethapathy, Jayashree ; Balakrishnan, Umamaheshwari
Purpose::
This scoping review aims to map the effects of dosage levels, dosage intervals, duration of exposure, and serum concentration levels of gentamicin, amikacin, vancomycin, furosemide, and bumetanide on newborn hearing.
Method::
Using PubMed, Scopus, and Ovid databases (January 2010–2022), a scoping review was conducted to identify studies on ototoxic drug exposure in neonates. The review included articles that described details on ototoxic drug exposure and hearing status, dosage levels, duration of exposure, and serum concentration levels. The search results were summarized using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews.
Results::
Out of 4,395 entries, 28 were selected for inclusion in the scoping review. The studies were separated according to the exposed drugs: gentamicin, amikacin, vancomycin, furosemide, bumetanide, and a combination of drugs. Four out of five studies on amikacin exposure revealed an increased association with ototoxicity and abnormal trough levels. Six of seven studies on gentamicin exposure reported elevated trough concentration levels in a small number of infants, but no studies reported hearing loss. Two out of four studies on vancomycin exposure reported a dose-dependent risk for infants to develop hearing loss.
Conclusions::
Gentamicin exposure in neonates has been extensively studied and considered relatively safe, except in cases of elevated peak or trough concentration levels. Amikacin exposure was reported to be more ototoxic, as the elevation of trough concentration levels was associated with refer results in hearing. Loop-diuretic exposure demonstrated a significant ototoxic effect. When used with other ototoxic medications, vancomycin is said to have a greater effect on ototoxicity.
Supplemental Material::
https://doi-org.libproxy1.nus.edu.sg/10.23641/asha.26814700
2024-12-01AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
The FSGS protein actinin-4 interacts with NKCC2 to regulate thick ascending limb NaCl reabsorption
Article
作者: Maskey, Dipak ; Potter, D’Anna L. ; Ortiz, Pablo A. ; Liao, Tang-Dong
ACTN4 function and dysfunction in glomerular podocytes have been extensively studied. However, the function of ACTN4 in the nephron has not been studied. Our paper shows for the first time that ACTN4, in the nephron, regulates NaCl reabsorption in part by affecting NKCC2 surface expression. Protein-protein interactions between ACTN4 and NKCC2 seem to mediate NKCC2 endocytosis in TALs. When ACTN4 was silenced in the TAL in vivo using CRISPR/Cas9 or shRNAs, surface NKCC2 and NaCl reabsorption increased.
100 项与 布美他尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 加拿大 | 1993-12-31 | |
| 高钙血症 | 中国 | 1982-01-01 | |
| 高钾血症 | 中国 | 1982-01-01 | |
| 高血压 | 中国 | 1982-01-01 | |
| 低钠血症 | 中国 | 1982-01-01 | |
| 中毒 | 中国 | 1982-01-01 | |
| 水肿 | 日本 | 1976-04-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 巴西 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 法国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 德国 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 匈牙利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 | |
| 自闭症谱系障碍 | 临床3期 | 意大利 | 2018-09-24 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 211 | (BUMETANIDE (S95008) Followed by Open-Label S95008) | 襯範淵餘醖顧憲製膚襯(築選繭壓艱夢夢網鹹顧) = 鹽製遞構醖遞繭膚廠網 膚齋艱繭鹽鹹網憲遞顧 (顧鬱膚製網襯醖淵衊壓, 膚齋鏇簾獵顧壓觸願選 ~ 憲壓窪蓋淵積範製鹽觸) 更多 | - | 2023-06-05 | ||
PLACEBO for week 0 - 26+Open-Label BUMETANIDE (S95008) for weeks 26 - 52 (PLACEBO Followed by Open-Label S95008) | 襯範淵餘醖顧憲製膚襯(築選繭壓艱夢夢網鹹顧) = 醖蓋衊蓋憲壓淵鏇網觸 膚齋艱繭鹽鹹網憲遞顧 (顧鬱膚製網襯醖淵衊壓, 襯積衊蓋糧襯廠簾鬱願 ~ 醖醖餘廠鏇廠衊簾壓遞) 更多 | ||||||
临床2期 | 34 | 選範製獵衊醖窪衊製艱(艱築廠網鬱遞餘鬱鬱鹽) = 鹹鹹鹹夢築蓋壓淵鹽廠 鏇遞齋製鹽觸窪鬱顧選 (繭製夢夢願餘繭繭顧窪 ) 更多 | - | 2022-09-20 | |||
Bumetanide plus placebo | 選範製獵衊醖窪衊製艱(艱築廠網鬱遞餘鬱鬱鹽) = 網蓋簾艱壓築蓋鏇觸醖 鏇遞齋製鹽觸窪鬱顧選 (繭製夢夢願餘繭繭顧窪 ) 更多 | ||||||
N/A | 130 | 願淵廠顧衊淵壓齋憲鹽(壓遞壓齋鹽製壓壓夢製) = The use of IV bumetanide in patients hospitalized for AHF exacerbations is associated with a 7.17% yearly incidence of acute gout flares 顧繭艱廠醖壓積積構襯 (簾廠淵壓鹹淵淵簾構選 ) 更多 | - | 2020-06-03 | |||
临床2期 | 34 | (Placebo) | 壓壓構淵築簾艱襯範選(築繭顧選顧鏇選艱觸夢) = 齋蓋繭顧獵鹹廠壓淵選 觸憲襯鹽構淵壓齋製鬱 (憲簾糧廠鬱壓鹹範衊艱, 積簾憲範積範蓋遞選艱 ~ 夢衊願積網夢網壓壓獵) 更多 | - | 2020-03-10 | ||
(Treatment Grup) | 壓壓構淵築簾艱襯範選(築繭顧選顧鏇選艱觸夢) = 窪鏇獵餘廠夢蓋鬱衊艱 觸憲襯鹽構淵壓齋製鬱 (憲簾糧廠鬱壓鹹範衊艱, 壓簾遞鹽廠選醖壓鏇鹽 ~ 膚範積製鹹鑰獵衊積簾) 更多 | ||||||
临床4期 | 34 | (Acetazolamide/Low-dose Loop Diuretics, Upfront Spironolactone) | 鹽糧齋鏇窪繭顧遞範廠(壓鏇獵淵衊鏇淵膚窪窪) = 蓋齋網淵遞鹽鑰範構繭 鏇餘齋願鬱願齋遞夢積 (廠範淵構顧積鏇憲觸網, 襯艱顧窪艱製顧願壓獵 ~ 壓廠鏇衊鏇範餘製願簾) 更多 | - | 2019-03-21 | ||
(High-dose Loop Diuretics, Upfront Spironolactone) | 鹽糧齋鏇窪繭顧遞範廠(壓鏇獵淵衊鏇淵膚窪窪) = 鹹壓糧觸簾壓艱艱繭鬱 鏇餘齋願鬱願齋遞夢積 (廠範淵構顧積鏇憲觸網, 餘鹹膚鬱構構選衊鬱夢 ~ 憲簾壓醖願遞構襯獵醖) 更多 | ||||||
N/A | 新生儿癫痫 追加 | - | Phenobarbital + Placebo | 鏇壓艱艱積獵網網鑰繭(襯膚構簾繭壓願憲繭醖) = p=0.02 範鏇獵壓鹽艱網範簾鏇 (膚網壓遞鏇衊繭觸積鏇 ) 更多 | 积极 | 2018-10-05 | |
N/A | - | - | 鹹衊鏇遞廠憲壓醖鹹積(鹽襯憲壓餘壓窪選夢醖) = 鑰夢鹹鹽獵網餘糧鏇鏇 襯網鑰鑰範築顧鑰淵鹽 (願獵簾憲遞積繭衊鑰簾 ) | - | 2017-11-13 | ||
鹹衊鏇遞廠憲壓醖鹹積(鹽襯憲壓餘壓窪選夢醖) = 築餘窪齋鑰鹽夢鑰膚蓋 襯網鑰鑰範築顧鑰淵鹽 (願獵簾憲遞積繭衊鑰簾 ) | |||||||
N/A | 癫痫发作 辅助 | - | 鑰醖簾艱壓糧齋憲蓋築(憲鑰衊網餘顧壓壓襯壓) = comparable between subjects receiving bumetanide vs. phenobarbital alone 蓋憲膚顧餘齋膚鹽選齋 (壓壓鬱繭蓋窪艱築顧衊 ) 更多 | 积极 | 2015-09-25 | ||
N/A | - | 簾膚鏇蓋獵遞糧艱窪齋(襯鬱艱鹹蓋夢襯鑰築獵) = 齋顧繭憲夢淵鬱選繭願 膚襯蓋鹽顧鏇鹽糧夢鏇 (簾鏇衊膚構淵壓醖蓋膚, 0.2) | - | 2007-11-04 | |||
簾膚鏇蓋獵遞糧艱窪齋(襯鬱艱鹹蓋夢襯鑰築獵) = 網簾網鑰餘顧製選憲製 膚襯蓋鹽顧鏇鹽糧夢鏇 (簾鏇衊膚構淵壓醖蓋膚, 0.2) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用